JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Cell lines
Jurkat CD4+ T cell leukemia cell line
Preparation method
The solubility of this compound in DMSO is > 17.4 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.
Reacting condition
2.5, 5, 10, 20 or 40 μM; 1 ~ 3 days
Applications
In Jurkat CD4+ T cell leukemia cell line, Orlistat, at the concentration of 40 μM, reduced O6-methylguanine-DNA methyltransferase (MGMT) expression by > 50% on day 2, whereas little or no effect was observed when lower concentrations were applied. The effect of Orlistat persisted on day 3. However, on day 1, Orlistat did not remarkably change the MGMT level.
Animal models
Nude mice bearing PC-3 tumors
Dosage form
155 mg/kg or 240 mg/kg/day; i.p.
In nude mice bearing PC-3 tumors, Orlistat at the dose of 240 mg/kg/day inhibited tumor growth and induced tumor cell apoptosis. A pharmacokinetic study of Orlistat (155 mg/kg) administered by i.p. injection showed the peak blood level of Orlistat (~10 μM) achieved 2 hrs after dosing. After 2hrs, the blood level of Orlistat decreased rapidly.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Cioccoloni G, Bonmassar L, Pagani E, Caporali S, Fuggetta MP, Bonmassar E, D'Atri S, Aquino A. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72.
[2]. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15;64(6):2070-5.
